AAAAAA
Results: 1-25/849
Authors:
Liras, A
Citation: A. Liras, Gene therapy for haemophilia: the end of a 'royal pathology' in the third millennium?, HAEMOPHILIA, 7(5), 2001, pp. 441-445
Authors:
Fischer, K
Van der Bom, JG
Mauser-Bunschoten, EP
Roosendaal, G
Prejs, R
Grobbee, DE
Van den Berg, HM
Citation: K. Fischer et al., Changes in treatment strategies for severe haemophilia over the last 3 decades: effects on clotting factor consumption and arthropathy, HAEMOPHILIA, 7(5), 2001, pp. 446-452
Authors:
Wallny, T
Hess, L
Seuser, A
Zander, D
Brackmann, HH
Kraft, CN
Citation: T. Wallny et al., Pain status of patients with severe haemophilic arthropathy, HAEMOPHILIA, 7(5), 2001, pp. 453-458
Authors:
Miners, AH
Sabin, CA
Tolley, KH
Parnaby, A
Lee, CA
Citation: Ah. Miners et al., Assessing the relationship between productivity levels and severity of haemophilia, HAEMOPHILIA, 7(5), 2001, pp. 459-463
Authors:
Jijina, F
Ghosh, K
Madkaikar, M
Mohanty, D
Citation: F. Jijina et al., Ophthalmic surgery in haemophilia, HAEMOPHILIA, 7(5), 2001, pp. 464-467
Authors:
Sonbol, H
Pelargidou, M
Lucas, VS
Gelbier, MJ
Mason, C
Roberts, GJ
Citation: H. Sonbol et al., Dental health indices and caries-related microflora in children with severe haemophilia, HAEMOPHILIA, 7(5), 2001, pp. 468-474
Molecular pathology of haemophilia A in Turkish patients: identification of 36 independent mutations
Authors:
Timur, AA
Gurgey, A
Aktuglu, G
Kavakli, K
Canatan, D
Olek, K
Caglayan, SH
Citation: Aa. Timur et al., Molecular pathology of haemophilia A in Turkish patients: identification of 36 independent mutations, HAEMOPHILIA, 7(5), 2001, pp. 475-481
Authors:
Kavakli, K
Huseyinov, A
Coker, I
Aydinok, Y
Nisli, G
Citation: K. Kavakli et al., Intraleucocyte platelet-activating factor levels in desmopressin-treated patients with haemophilia A and von Willebrand disease, HAEMOPHILIA, 7(5), 2001, pp. 482-489
Authors:
Hodge, G
Han, P
Citation: G. Hodge et P. Han, Factor VIII concentrate inhibits T helper type 2 cytokine production in vitro: relevance to inhibitor antibody formation, HAEMOPHILIA, 7(5), 2001, pp. 490-496
Authors:
Gilchrist, GS
Wilke, JL
Muehlenbein, LR
Danilenko-Dixon, D
Citation: Gs. Gilchrist et al., Intrauterine correction of factor VIII (FVIII) deficiency, HAEMOPHILIA, 7(5), 2001, pp. 497-499
Authors:
Zanon, E
Vianello, F
Casonato, A
Girolami, A
Citation: E. Zanon et al., Early transfusion of factor VIII/von Willebrand factor concentrates seems to be effective in the treatment of gatrointestinal bleeding in patients with von Willebrand type III disease, HAEMOPHILIA, 7(5), 2001, pp. 500-503
Authors:
Mukhopadhyay, S
Saxena, R
Kashyap, R
Choudhry, VP
Citation: S. Mukhopadhyay et al., Danazol therapy in factor X deficiency, HAEMOPHILIA, 7(5), 2001, pp. 504-506
Authors:
Hothi, DK
Kelsall, W
Baglin, T
Williams, DM
Citation: Dk. Hothi et al., Bacterial endocarditis in a child with haemophilia B: risks of central venous catheters, HAEMOPHILIA, 7(5), 2001, pp. 507-510
Authors:
Vianello, F
Belvini, D
Dal Bello, F
Tagariello, G
Zanon, E
Lombardi, AM
Zerbinati, P
Girolami, A
Citation: F. Vianello et al., Mild bleeding diathesis in a boy with combined severe haemophilia B (C-10400 -> T) and heterozygous factor V Leiden, HAEMOPHILIA, 7(5), 2001, pp. 511-514
Authors:
Ghosh, K
Shetty, S
Mohanty, D
Citation: K. Ghosh et al., Haemorrhage in upper cervical cord: an unusual manifestation in moderate haemophilia patients who ride motorbikes, HAEMOPHILIA, 7(5), 2001, pp. 515-516
Authors:
Cooper, HA
Jones, CP
Campion, E
Roberts, HR
Hedner, U
Citation: Ha. Cooper et al., Rationale for the use of high dose rFVIIa in a high-titre inhibitor patient with haemophilia B during major orthopaedic procedures, HAEMOPHILIA, 7(5), 2001, pp. 517-522
Authors:
Meiklejohn, DJ
Watson, HG
Citation: Dj. Meiklejohn et Hg. Watson, Acquired haemophilia in association with organ-specific autoimmune disease, HAEMOPHILIA, 7(5), 2001, pp. 523-525
Authors:
Regina, S
Colombat, P
Fimbel, B
Guerois, C
Gruel, Y
Citation: S. Regina et al., Acquired inhibitor to factor VIII in a patient with Hodgkin's disease following treatment with interferon-alpha, HAEMOPHILIA, 7(5), 2001, pp. 526-527
Authors:
Gassel, F
Kraft, CN
Wallny, T
Hess, L
Schmitt, O
Citation: F. Gassel et al., Soft-tissue angioleiomyoma of the hand as a rare differential diagnosis ofhaemophilic pseudotumour, HAEMOPHILIA, 7(5), 2001, pp. 528-531
Authors:
Chuansumrit, A
Sri-Udomporn, N
Srimuninnimit, V
Juntarukha, R
Citation: A. Chuansumrit et al., A single high dose of recombinant factor VIIa combining adjuvant therapy for controlling bleeding episodes in haemophiliacs with inhibitors, HAEMOPHILIA, 7(5), 2001, pp. 532-534
Authors:
Shittu, OB
Shokunbi, WA
Citation: Ob. Shittu et Wa. Shokunbi, Circumcision in haemophiliacs: the Nigerian experience, HAEMOPHILIA, 7(5), 2001, pp. 534-536
Authors:
Makris, M
Baglin, T
Dusheiko, G
Giangrande, PLF
Lee, CA
Ludlam, CA
Preston, FE
Watson, HG
Wilde, JT
Winter, M
Citation: M. Makris et al., Guidelines on the diagnosis, management and prevention of hepatitis in haemophilia, HAEMOPHILIA, 7(4), 2001, pp. 339-345
Authors:
Scharrer, I
Ehrlich, HJ
Citation: I. Scharrer et Hj. Ehrlich, Lack of evidence for increased inhibitor incidence in patients switched from plasma-derived to recombinant factor VIII, HAEMOPHILIA, 7(4), 2001, pp. 346-348
Authors:
Rizza, CR
Hill, FGH
Spooner, RJD
Giangrande, PLF
Citation: Cr. Rizza et al., Treatment of haemophilia in the United Kingdom 1981-1996, HAEMOPHILIA, 7(4), 2001, pp. 349-359
Authors:
Berntorp, E
Petrini, P
Dockter, G
Tengborn, L
Wendisch, I
Eberl, W
Aumann, V
Frade, G
Seliger, I
Engl, W
Ehrlich, H
Citation: E. Berntorp et al., An approach to study the viral safety of plasma-derived products in previously treated, non-infected patients, HAEMOPHILIA, 7(4), 2001, pp. 360-363